Background– Letrozole, the aromatase inhibitor has been reported to decrease the size of symptomatic fibroid & uterine volume with improvement in the haemoglobin levels and pain. Method–100 cases, from department of Gynae. & Obst. , PBM Hospital , SPMC ,Bikaner were included in this study from 1st Aug. 2017 to 31th July. 2018. After complete general & Gynaecological evaluation, all 100 cases were prescribe to take tab. Letrozole 5mg/day continuously for 3 months & effects of the drugs were observed. Result–Average reduction of fibroid volume by 23.65 % and uterine volume by 69.45% was seen. Haemoglobin concentration increased from 8.4 g/dl to 10.4g/dl and overall improvement in symptomatology score was observed. Joint pain, hot flushes , sweating, hair loss & hyper pigmentation were the main adverse effects observed and were self limiting . Conclusion– Letrozole the aromatase inhibitor may represent a new generation of medication for the treatment of uterine fibroid and associated symptoms. Larger clinical trials are needed, however, to fully evaluate their safety and efficacy.